ArticleBiological trace element research2026
Chromium Mitigates the Iron-Induced Glucose Metabolism Disorder via the PI3K/Akt/Bcl-2 Signaling Pathway: An In Vivo Study in Wistar Rats.
Article in Biological trace element research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Numerous studies have focused on the independent effects of iron and chromium on type 2 diabetes mellitus (T2DM); however, studies on their combined effects remain limited. Therefore, we examined the combined effects of chromium and iron on glucose metabolism using an in vivo Wistar rat model. Male Wistar rats (N = 30) were divided into five groups: control (Ctr), iron excess (IE), and three chromium-treated groups receiving low, medium, or high doses of chromium picolinate (IEC1-3). Rats were fed diets with adequate or excess iron (as iron citrate) and varying doses of chromium for 8 weeks. Glucose metabolism, oxidative stress markers, histopathology of pancreatic tissue, and PI3K/Akt/Bcl-2-related gene and protein expression in pancreatic tissue were evaluated. We observed a significant increase in fasting blood glucose (FBG) and insulin resistance in the IE group. Iron excess increased serum malondialdehyde (MDA), reduced superoxide dismutase (SOD) activity, downregulated phosphorylation of phosphatidylinositol 3-kinase (p-PI3K), phospho-protein kinase B (p-Akt) proteins, and B-cell lymphoma 2 (Bcl-2), and upregulated Bax and cleaved caspase-9 in pancreatic tissue, leading to pancreatic β-cell apoptosis. In contrast, chromium supplementation reversed these effects, improving pancreatic β-cell apoptosis and glucose metabolism. Our findings suggest that chromium may attenuate iron-induced pancreatic β-cell apoptosis and glucose metabolism impairment, potentially by reducing oxidative damage and modulating the PI3K/Akt/Bcl-2 signaling pathway. These results highlight a potentially protective role of chromium in the context of iron excess, which could inform future research into nutritional interventions for metabolic disorders. Further studies are warranted to fully elucidate the underlying mechanisms and translational applicability.
Indexed as
Identifiers
41108476What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.